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HRAS-mutant head and neck squamous cell carcinoma (HNSCC) is a rare and deadly cancer type, 
for which effective treatments are currently lacking. HRAS-mutant HNSCC patients have shown 
sensitivity to the farnesyl transferase inhibitor (FTI) tipifarnib clinically. Tipifarnib inhibits the 
membrane association of HRAS, a small GTPase that activates many cell-signaling pathways that 
are associated with the growth, maintenance and survival of cancer cells. We investigated 
whether treatment of HRAS-mutant HNSCC cell lines with tipifarnib induced common 
mechanisms of resistance to cancer therapeutics. Indeed, we found that proteins in the MAPK 
and PI3K-AKT-mTOR signaling pathways were activated upon treatment with tipifarnib, 
suggesting compensatory activation of these pathways as a possible mechanism of resistance in 
our cell lines. We next tested whether tipifarnib induced epithelial to mesenchymal transition 
(EMT). EMT results in improved migratory ability, increased invasiveness, and enhanced 
resistance to apoptosis. Using immunoblotting and immunofluorescence microscopy, we 
observed an upregulation in markers of EMT upon treatment with tipifarnib. A subset of HRAS-
mutant HNSCC cell lines have shown sensitivity to the inhibition of ERK, with the ERK inhibitor 
SCH772984, in combination with other therapeutics. ERK is a downstream effector of HRAS. 
Previous studies have shown that induction of autophagy is a mechanism of resistance to ERK 
inhibition with SCH772984 treatment in some RAS-mutant cancers. Autophagy is the process 
through which cells recycle proteins and cytoplasmic organelles in response to stress. We found 
that SCH772984 induced autophagic flux. We did not observe an increase in apoptosis upon 
simultaneous inhibition of autophagy and ERK, however, suggesting that autophagy may not be 




several possible mechanisms of resistance of HRAS-mutant HNSCC cell lines to targeted 




Head and neck squamous cell carcinoma (HNSCC) is the seventh most common type of cancer 
worldwide, with approximately 900,000 cases diagnosed each year (Bray et al. 2018). Risk factors 
for HNSCC include exposure to carcinogens, such as tobacco and alcohol, and infection with the 
human papillomavirus (HPV) (Chow 2020). HPV infection is associated with an estimated 18% to 
28% of HNSCC cases (Gillison et al. 2015). Of HPV-negative cases, which tend to have a worse 
prognosis, approximately 5% are fueled by mutations in the HRAS oncogene (Cancer Genome 
Atlas Network 2015). Current treatments for HNSCC negatively impact the quality of life of 
patients, and can be debilitating and disfiguring, making it imperative to find more effective 
treatments for this disease (Chow 2020). Inhibiting the molecular requirements for HRAS 
function and understanding how cancer cells might resist this inhibition can help achieve this goal 
for the subset of HNSCC cases fueled by mutations in the HRAS oncogene.                                                                                                                                        
 
HRAS is one isoform within the RAS protooncogene family, which also includes KRAS and NRAS. 
Different RAS isoforms are preferentially mutated in different forms of cancer, with HRAS the 
isoform mutated most frequently in HNSCC (Prior et al 2020). RAS mutations as a whole are found 
in up to 30% of all human cancers, and are among the most prevalent mutations in the deadliest 
cancer types (Cox et al. 2014). RAS is a small GTPase enzyme that regulates many cellular 
processes, including growth, survival and proliferation. Mutated RAS proteins fail to transition 




activate cell signaling cascades, leading to excess cell growth and division. RAS signaling 
influences various cell signaling pathways that are frequently involved in cancer maintenance, 
including the RAF-MEK-ERK (MAPK) and PI3K-AKT-mTOR cascades (Cox et al. 2014). 
 
Several different approaches to RAS inhibition have been studied as possible targeted 
therapeutic strategies, all of which target the molecular requirements for RAS function. RAS 
proteins must localize to the plasma membrane for proper function (Willumsen et al. 1984). 
Membrane association occurs via posttranslational modifications at the RAS C-terminal CAAX (c 
= cysteine, A = aliphatic amino acid, X = variable amino acid) motif. A 15-carbon farnesyl 
polyisoprene lipid is added by the enzyme farnesyltransferase (FTase) to the cysteine of the CAAX 
motif, and the AAX amino acids are cleaved. The carbonyl group on the C-terminal 
farnesylcysteine is then methylesterified, creating a RAS protein with a hydrophobic tail and 
membrane affinity. Because FTase activity is essential and rate-limiting for RAS membrane 
association, FTase inhibitors (FTIs) have been well-studied for prevention of RAS membrane 
association and the subsequent inhibition of aberrant RAS function (Ahearn et al. 2018).  FTIs 
successfully inhibit the membrane association of HRAS (Fig. 1) but not of KRAS or NRAS, which 
are recruited to the cell membrane via alternative prenylation (Whyte et al. 1997). The FTI 
tipifarnib has advanced to phase II clinical trials for the treatment of HRAS-mutant HNSCC, and 
has shown some efficacy (Ho et al. 2017). Despite this early success in using tipifarnib to treat 
HRAS-mutant HNSCC, the eventual development of a widely effective treatment for this disease 
depends on further investigation of the mechanisms through which cancer cells may be able to 















Because KRAS- and NRAS-mutant cancers are not susceptible to FTIs, additional attempts to stop 
aberrant RAS function have focused on inhibiting its downstream effectors. Many of these 
inhibitors have been clinically evaluated, and several have been approved to treat RAS-mutant 
cancers. Proteins involved in the RAF-MEK-ERK cascade are common pharmacological targets for 
such inhibition (Cox et al. 2014). ERK1/2 is a serine/threonine kinase whose activity is most 
effectively blocked by direct inhibition, because it is regulated by a complex network of proteins 
and has more than 200 substrates (Kidger et al. 2018). SCH772984 is an allosteric and ATP-
competitive ERK1/2 inhibitor that has been shown to inhibit ERK activity in RAS-mutant cancers 
(Morris et al. 2013) (Fig 1). Our lab has previously found that a subset of HRAS-mutant HNSCC 
cell lines are sensitive to ERK inhibition with SCH772984 in combination with other treatments. 
Understanding the ways in which these cells might resist the effects of ERK inhibition is an 
Figure 1. Schematic showing how tipifarnib and SCH772984 






important step in determining whether ERK inhibition might eventually be an effective treatment 
option for HRAS-mutant HNSCC.    
 
The induction of resistance to targeted therapeutic agents interferes with their efficacy in cancer 
treatment.  A common mechanism is the upregulation of cell-signaling pathways involved in 
cancer maintenance.  Cancer cells may also undergo EMT to evade targeted therapeutic agents 
(Derynck and Weinberg 2019). EMT occurs when biochemical changes in epithelial cells lead to 
their assuming a mesenchymal phenotype, resulting in improved migratory ability, increased 
invasiveness, and enhanced resistance to apoptosis (Kalluri and Weinberg 2009). EMT is directly 
linked to cytoskeletal and morphological changes (Sun et al. 2015). Previous studies have 
connected FTI treatment to EMT-related changes in cell morphology in KRAS-transformed cells 
(Suzuki et al. 1998), suggesting that induction of EMT could be a mechanism of resistance to FTI 
treatment. Cancer cells may also exhibit an autophagic response to therapeutics as a protective 
strategy. Autophagy is the process through which cells break down and recycle proteins and 
cytoplasmic organelles in response to starvation or stress. Induction of autophagy can provide 
cancer cells with nutrients that fuel their metabolic needs, or allow them to remove organelles 
or proteins that are damaged by cytotoxic agents (Kondo et al. 2005). The ERK inhibitor 
SCH772984 increased autophagy in KRAS-mutant pancreatic ductal adenocarcinoma (Bryant et 
al. 2019). Combined inhibition of autophagy and ERK increased apoptosis, suggesting protective 
autophagy as a mechanism of resistance to ERK inhibition in a RAS-mutant cancer type (Bryant 






Our knowledge of common mechanisms of resistance to cancer therapeutics and our desire to 
help uncover more efficacious treatments for HRAS-mutant HNSCC led us to explore whether 
tipifarnib or SCH779284 led to induction of the aforementioned mechanisms of resistance in 
HRAS-mutant HNSCC cell lines. Here, using a variety of immunofluorescence microscopy and 
immunoblotting techniques, we demonstrate that the FTI tipifarnib paradoxically increased 
activation of the MAPK and PI3K-AKT-mTOR signaling pathways, and induced an epithelial to 
mesenchymal transition in HRAS-mutant HNSCC cell lines. These results suggest two possible 
mechanisms of resistance of HRAS-mutant HNSCC to tipifarnib treatment. We also show that the 
ERK inhibitor SCH772984 induced autophagy in HRAS-mutant HNSCC cell lines. However, 
combined inhibition of ERK and autophagy did not increase apoptosis, suggesting that protective 
autophagy is not a mechanism of resistance to ERK inhibition in these cell lines. Overall, our 
results provide important insight into possible mechanisms of resistance to targeted therapies, 
which can help inform the future development of effective treatments for HRAS-mutant HNSCC.  
 
Methods: 
Cell lines and culture: HPV-negative HRAS-mutant HNSCC cell lines HN30, UMSCC4 and KYSE30 
were maintained at 37°C and 5% CO2. HN30 (HRAS G12D) was a gift from Dr. Silvio Gutkind 
(University of California at San Diego). These cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) (ThermoFisher Scientific), supplemented with 10% fetal bovine serum (FBS) and 
penicillin/streptomycin. UMSCC4 (HRAS G12V) was acquired from the University of Michigan, 
Ann Arbor, through a materials transfer agreement, and maintained in DMEM (ThermoFisher 




penicillin/streptomycin. KYSE30 (HRAS Q61L) was obtained from the Tissue Culture Facility at the 
Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, and was maintained in a 1:1 ratio 
of RPMI 1640 and Ham’s F-12 nutrient mix (ThermoFisher Scientific) with 2% FBS and 
penicillin/streptomycin. Cell lines were STR-authenticated and regularly monitored for 
mycoplasma infection. 
Antibodies: Antibodies were diluted in 1x TBS with 0.1% Tween 20 (TBST) and 5% BSA (Sigma).                                                   
Antibody name Dilution Source Catalog number 




1:1,000 Cell Signaling Technology 4370 
ZEB1 1:250 Abcam  Ab203829 
HRAS 1:1,000 Cell Signaling Technology 18295-1-AP 
ERK 1:1,000 Cell Signaling Technology 4696 
AKT 1:1,000 Cell Signaling Technology 9272 
vimentin 1:1,000 Cell Signaling Technology 5741 
E-cadherin 1:1,000 Cell Signaling Technology 3195 
vinculin 1:5,000 Sigma hVIN1 
Amersham ECL donkey anti-
rabbit IgG, HRP-linked whole Ab  
1:5,000 GE Healthcare NA934V 
Amersham ECL sheep anti-
mouse IgG, HRP-linked whole 
Ab  








Inhibitors: Tipifarnib and chloroquine were acquired from Selleckchem. SCH772984 was kindly 
provided by Merck. 
Western blot analysis: For sample preparation, treated cells were washed twice with cold PBS 
and lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM 
Tris pH 8.0), supplemented with protease inhibitor (Roche, 0589297000) and phosphatase 
inhibitor (EMD-Millipore 524624 and 524625). Lysates were centrifuged at a rate of 14,000 x g 
for 15 minutes at 4°C to remove cell debris.  Total protein was quantified using the Bradford 
method (BioRAD 500111), and equalized between samples. Protein samples were suspended in 
4x Laemmli sample buffer (Bio-Rad), supplemented with β-mercaptoethanol, and boiled for 5 
minutes. Equal volumes of samples (25 μL/well) were used for SDS-PAGE. Proteins were 
transferred to a PVDF membrane. Membranes were blocked with 5% milk at 37°C for 1 hour and 
washed in TBS with 0.1% Tween 20 (TBST). Membranes were then incubated with diluted primary 
antibodies overnight at 4°C. After washing 3 times for 10 minutes at RT with TBST, membranes 
were incubated in the appropriate secondary antibody for 45 minutes at RT.  Proteins were 
detected by chemiluminescence (Amersham ECL Western Blotting Detection Kit, GE Life 
Sciences) and blots were developed using the ChemiDoc MP Imaging System (BioRad). 
Densitometry analysis of western blots was performed using ImageJ. 
Autophagic Flux Assay: HN30 cells were plated on glass bottom dishes (MatTek) and transfected 
with mCherry-EGFP-LC3B using a pBabe-puro retroviral expression vector, kindly provided by K. 
Bryant (UNC Chapel Hill). Cells were treated with 400 nM SCH772984 for 48 hours. Cells were 




laser lines were used to excite mCherry-EGFP-LC3B for quantification of autophagic flux. 
Expression of both EGFP and mCherry indicates formation of autophagosomes. Expression of 
mCherry alone indicates the formation of autolysosomes, characterizing autophagic flux (Bryant 
et al. 2019). ImageJ was used to analyze images and quantify fluorescence, as described 
previously (Commisso et al., 2014). Autophagic index represents the ratio of mCherry+ to EGFP+ 
punctae, and is a quantification of autophagic flux. 
Apoptosis Assay: HN30, KYSE30 and UMSCC4 cell lines were treated with 3 µM chloroquine or 
400 nM SCH772984 or a combination of the two for 5 days. Cells were washed with PBS and 
detached using 0.05% trypsin-EDTA (ThermoFisher Scientific). Detached cells and culture 
medium were combined and centrifuged at 1.0 x g for 5 minutes at RT. Pellets were washed 
again with PBS and centrifuged again at 1.0 x g for 5 minutes. An Annexin V-FITC Apoptosis 
Detection Kit (ThermoFisher Scientific) was used to measure apoptosis. Cells were incubated in 
Annexin-V incubation reagent (1% Annexin-V FITC, 1x propidium iodide, in 1x binding buffer) in 
the dark for 15 minutes at RT. 1x binding buffer was added to cells, which were then processed 
using flow cytometry (CytoFLEX S, Beckman Coulter). Annexin-V positive, propidium iodide 
negative cells were considered to be apoptotic. Annexin-V positive, propidium iodide positive 
cells were considered to be necrotic. 
Immunofluorescence Microscopy. HN30, UMSCC4 and KYSE30 cells were plated in MatTek 
dishes and treated with 200 nM tipifarnib for 5 days. Culture medium was removed, cells were 
washed using 1x PBS and fixed using 3.7% formaldehyde (Fisher Scientific) for 10 minutes at RT. 




minutes at RT. This was followed by incubation in primary antibody (diluted in 2% BSA-PBS) for 
40 minutes at RT, 3 washes with 1x PBS, and incubation in secondary antibody (diluted in 2% 
BSA-PBS) for 45 min at RT. For visualization of E-cadherin and F-Actin, cells were then mounted 
with Prolong Diamant anti-fade mounting medium (Invitrogen). For visualization of ZEB1, cells 
were maintained in MatTek dishes at 4°C, in PBS with 0.04% sodium azide, until imaged. E-
cadherin was visualized a using rabbit-anti-E-cadherin primary antibody (1:100) and a goat-anti-
rabbit Alexa-Fluor-568 conjugated secondary antibody. F-actin was visualized using phalloidin 
conjugated with an Alexa-488 fluorophore (Invitrogen, 1:200, A12379). ZEB1 was visualized 
using a rabbit-anti-ZEB1 primary antibody (1:250) and a goat-anti-rabbit Alexa-Fluor-568 
conjugated secondary antibody. DAPI (Invitrogen, 1:10,000) was used to label the nucleus. E-
cadherin and F-actin images were acquired on an Olympus FV1000 confocal microscope using a 
40x objective (1.2 zoom).  ZEB1 images were acquired on an EVOS M7000 confocal microscope 
using a 60x objective. DAPI nuclear signal was used to create a binary mask and isolate nuclear 
ZEB1.  Relative intensity represents the sum of all pixels within the nuclear region, normalized 
with the intensity of the vehicle-treated control. Relative intensity of nuclear ZEB1 was 
quantified using ImageJ. 
Statistical Analysis: All experiments were done in at least two biological replicates. Data were 
analyzed using Excel (Microsoft). Data were normalized to their respective controls. For all 
graphs, error bars are indicative of mean ± standard deviation. A two-tailed t-test was used to 







Increased activation of MAPK and AKT signaling pathways occurs upon treatment with the FTI 
tipifarnib in a subset of HRAS-mutant HNSCC cell lines.  
Previous studies have focused on how treatment with FTIs affects signaling downstream of RAS. 
The RAF-MEK-ERK MAPK and PI3K-AKT-mTOR signaling cascades are important downstream 
effectors of RAS that are frequently involved in oncogenesis (Cox et al. 2014). To investigate the 
effects of the farnesyltransferase inhibitor tipifarnib on MAPK and AKT signaling in HRAS-mutant 
HNSCC, we treated HN30, KYSE30 and UMSCC4 cell lines with 200 nM tipifarnib for 5 days. This 
concentration of tipifarnib causes target inhibition without perturbing cell growth. Western 
blotting was used to visualize changes in the levels of phospho-ERK and phospho-AKT. We found 
Figure 2. pERK and pAKT are upregulated in a subset of HRAS-mutant HNSCC cell lines upon 
treatment with FTI. (A) Western blots showing pERK and pAKT protein levels. Cells were treated 
with 200 nM tipifarnib for 5 days. (B) Quantification of the ratio of phospho-AKT and phospho-
ERK to total protein, as represented in panel A. Data represents the mean of 2 independent 






that pERK and pAKT levels were increased in all three cell lines following tipifarnib treatment (Fig. 
2A and B), demonstrating compensatory activation of the MAPK and AKT signaling pathways in 
HRAS-mutant HNSCC in response to tipifarnib treatment. 
Tipifarnib causes morphological changes and epithelial to mesenchymal transition in HRAS-
mutant HNSCC cell lines.  
Induction of EMT has been linked to increased resistance to cancer therapeutics (Derynck and 
Weinberg 2019).  Previous studies have shown that treatment with FTIs causes changes in actin-
mediated cell morphology (Suzuki et al. 1998), which is linked to EMT (Sun et al. 2015). To 
investigate whether treatment with the FTI tipifarnib caused cytoskeletal changes and induced 
EMT in HRAS-mutant HNSCC, HN30, KYSE30 and UMSCC4 cells were treated with 200 nM 
tipifarnib for 5 days. We used immunofluorescence microscopy to visualize changes in F-actin 
and E-cadherin, and western blotting to evaluate changes in expression of E-cadherin and 
vimentin.  E-cadherin is a transmembrane junction protein that regulates cell adhesion in 
epithelial cells; loss of E-cadherin is considered a hallmark of EMT (Loh et al. 2019). Vimentin is a 
protein that is expressed in cytoskeletal intermediate filaments as cells transition to 
mesenchymal morphology. It plays an important role in EMT-related changes in cell adhesion, 
shape, and motility, and is often used as a marker for induction of EMT (Mendez et al. 2010). We 
observed changes in cytoskeletal morphology in all three cell lines through visualization of F-actin 
(Fig. 3A). Our results show a decrease in levels of E-cadherin in HN30 and UMSCC4 cells, and an 
increase in levels of vimentin in all 3 cell lines (Fig. 3A and B). These results demonstrate that 





Nuclear ZEB1 expression decreases in response to tipifarnib treatment  
Increased expression of the transcription factor ZEB1 is frequently linked to EMT (Zhang et al. 
2015). Accordingly, we hypothesized that the EMT related changes observed in response to 
tipifarnib treatment in HRAS mutant HNSCC cell lines could be linked to increased nuclear ZEB1 
expression. To test this hypothesis, we treated HN30, KYSE30 and UMSCC4 cell lines with 200 
nM tipifarnib for 5 days. This concentration of tipifarnib causes target inhibition without 
perturbing cell growth, and was the same concentration used to evaluate the effect of tipifarnib 
on other EMT markers. We then used immunofluorescence microscopy to visualize changes in 
nuclear ZEB1 intensity (Fig. 4A). Because ZEB1 acts as a transcription factor, visualizing its 
nuclear expression can provide insight into its activity as a mediator of transcription. 
Interestingly, we observed that intensity of nuclear ZEB1 decreased significantly in all cell lines 
in response to tipifarnib treatment, when compared to vehicle-treated controls (Fig. 4B). We 
also observed considerable heterogeneity in ZEB1 expression between different HNSCC cell 
lines. For example, in vehicle-treated HN30 and KYSE30 cells, ZEB1 was not localized solely to 
the nucleus, but was dispersed throughout the cell. Following treatment with tipifarnib, ZEB1 
appeared to localize more specifically to the nucleus, but overall expression of nuclear ZEB1 
decreased. In both tipifarnib treated and vehicle treated UMSCC4 cells, ZEB1 was concentrated 
in the nucleus (Fig. 4B). Despite this heterogeneity, nuclear ZEB1 decreased following tipifarnib 
treatment in all three cell lines, indicating that tipifarnib-induced EMT in HRAS-mutant HNSCC 



























Figure 3. An increase in EMT markers was observed in HRAS-mutant HNSCC cell lines upon 
treatment with tipifarnib. (A-C) Cells were treated with 200 nM tipifarnib for 5 days. (A) 
Photomicrographs showing expression and distribution of F-actin and E-cadherin. Scale bar = 20 
μm. (B) Western blots showing levels of vimentin and E-cadherin expression.  (C) Quantification 
of E-cadherin and vimentin expression as shown in panel B. Data represents the mean of 2 
































Figure 4. A decrease in relative intensity of nuclear ZEB1 was observed in HRAS-mutant HNSCC 
cell lines in response to tipifarnib treatment. (A-B) Cells were treated with 200 nM tipifarnib 
for 5 days. (A) Representative photomicrographs showing overall ZEB1 expression and nuclear 
ZEB1 intensity. Scale bar = 50 μm (B) Quantification of relative nuclear intensity of ZEB1. Data is 
represented as relative integrated intensity of ZEB1 from 20 different fields and 2 independent 























ERK inhibition induces autophagic flux in HRAS-mutant HNSCC cell lines. 
Induction of autophagy has the potential to be a mechanism of resistance to targeted therapeutic 
treatments, as autophagy can provide cancer cells with metabolic support in times of stress or 
starvation (Kondo et al. 2005). It has been previously shown that ERK inhibition with the inhibitor 
SCH772984 causes an increase in autophagy in KRAS mutant pancreatic ductal adenocarcinoma 
(PDAC) (Bryant et al. 2019). To evaluate whether ERK inhibition induced autophagy in HRAS-
mutant HNSCC, we transfected HN30 cells with a mCherry-EGFP-LC3B reporter protein, which 
allows for the visualization of the onset of autophagic flux. LC3B is a protein involved in 
autophagy that associates with autophagic vesicles. Expression of both mCherry and EGFP 
indicates the formation of autophagosomes. Expression of mCherry alone indicates the 
formation of autolysosomes, because EGFP loses fluorescence due to the acidic conditions 
associated with their formation (Fig. 5A). We treated transfected cells with a concentration of 
SCH772984 sufficient for complete target inhibition (400 nM) for 48 hours, quantified the 
number of mCherry and EGFP expressing punctae and calculated the ratio to obtain the 
autophagic index, which is a quantification of autophagic flux. We found that ERK inhibition does 
lead to induction of autophagic flux in HN30 cells (Fig. 5B). 
 Combined inhibition of ERK and autophagy does not cause apoptosis. 
In KRAS-mutant PDAC, combined inhibition of ERK and of autophagy, using the autophagy 
inhibitor chloroquine, resulted in increased levels of apoptosis (Bryant et al. 2019). To evaluate 
whether the same was true of HRAS-mutant HNSCC cell lines, we treated HN30, KYSE30 and 




Annexin-V and propidium iodide were used to stain apoptotic and necrotic cells, respectively, 
which were quantified using flow cytometry. We found no significant increase in the percent 




Figure 5. ERK inhibition induces autophagic flux but combined inhibition of ERK and autophagy 
does not cause apoptosis. (A-B) HN30 cells transfected with a mCherry-EGFP-LC3B marker were 
treated with 400 nM SCH772984 for 2 days. (A) Representative photomicrographs showing 
autophagic flux in HN30 cells. Expression of both EGFP and mCherry indicates formation of 
autophagosomes. Expression of mCherry alone indicates the formation of autolysosomes, 
characterizing autophagic flux. (B) Quantification of autophagic flux in HN30 cells treated with 400 
nM SCH772984 for 2 days. Data is represented as the mean of the ratio of mCherry to EGFP positive 
punctae from 8 different fields. **p<0.01. (C)  Quantification of apoptosis in HRAS-mutant HNSCC 
cell lines treated with 400 nM SCH772984, 3 µM chloroquine or a combination of the two for 5 days. 

























alone (Fig. 5C), suggesting that ERK-inhibitor-induced autophagy is not a mechanism of resistance 
to ERK inhibition in HRAS-mutant HNSCC cell lines. 
Discussion: 
Our results show that tipifarnib treatment leads to increased levels of pERK and pAKT in HRAS-
mutant HNSCC cell lines. This demonstrates activation of the MAPK and PI3K-AKT-mTOR cell 
signaling pathways in response to this treatment, and suggests a possible mechanism of 
resistance to tipifarnib. In agreement, it has previously been shown that tipifarnib treatment 
similarly increases MAPK and PI3K-AKT-mTOR signaling in HRAS-mutant thyroid cancer (Untch et 
al. 2018). Increased activation of these pathways has been seen previously as a mechanism of 
resistance to a variety of therapeutic agents. For example, MAPK upregulation has been found to 
confer resistance to microtubule-targeting drugs in prostate cancer (Liu et al. 2015), and to BRAF 
inhibitors in several cancer types (Lito et al 2017). Similarly, upregulation of the PI3K-AKT-mTOR 
pathway has also been implicated as a mechanism of resistance to BRAF inhibition in melanoma 
(Shi et al. 2014), and to cisplatin, a common DNA-damaging anti-cancer drug, in lung cancer (Liu 
et al. 2007). Interestingly, a very recent study of tipifarnib treatment in HRAS-mutant HNSCC 
found a reduction in MAPK signaling upon tipifarnib treatment (Gilardi et al. 2020). This 
discrepancy may be due to the use of different experimental conditions, which highlights the 
need for further investigation of the molecular changes underlying increased activation of the 
MAPK and PI3K-AKT-mTOR pathways in response to tipifarnib. Because upregulation of these 
pathways is a potential mechanism of resistance to tipifarnib treatment in HRAS-mutant HNSCC, 




inhibitors and tipifarnib in HRAS-mutant HNSCC. Many inhibitors of these pathways have been 
approved as cancer treatments (Braicu et al. 2019, Marquard and Jücker 2019). 
Our results also demonstrated that tipifarnib treatment led to a decrease in E-cadherin, an 
increase in vimentin, and to morphological changes- particularly cell enlargement - in HRAS-
mutant HNSCC. These findings suggest that tipifarnib treatment induces EMT. Interestingly, this 
differs from results seen in FTI-treated RAS-transformed fibroblast models, which saw cells revert 
to a more epithelial-like-morphology (Prendergast et al. 1994). Investigation of additional EMT 
markers could help confirm that EMT is occurring in response to tipifarnib treatment in HRAS-
mutant HNSCC cell lines. Decreased levels of E-cadherin and increased levels of vimentin are 
prototypical indicators of EMT in wildtype cells (Loh et al. 2019, Mendez et al. 2010), but further 
validation of this transition in HRAS-mutant HNSCC cells can be achieved through the 
investigation of additional EMT markers. It is important to note that cancer cells do not always 
undergo EMT that is typical of wildtype cells. Instead, these cells can undergo partial EMT, and 
may not adhere to the loss or gain of stereotypical EMT markers, making it necessary to evaluate 
this phenomenon from multiple angles (van Staalduinen et al. 2018). In addition to encouraging 
future studies of tipifarnib-induced changes in EMT markers, this knowledge of atypical EMT in 
cancer cells can also help explain why we did not observe a clear decrease in E-cadherin in KYSE30 
cells.  
Interestingly, we also observed that treatment with tipifarnib led to decreased expression of 
nuclear ZEB1 in HRAS-mutant HNSCC cells. ZEB1 is a transcription factor whose increased 




which leads to induction of EMT. Its activity is also involved in altering the expression of other 
proteins involved in EMT (Zhang et al. 2015). Our paradoxical observation that ZEB1 expression 
decreased in response to tipifarnib treatment highlights the need for further investigation of the 
molecular mechanisms underlying tipifarnib-induced, EMT-related changes in E-cadherin and 
vimentin in HRAS-mutant HNSCC cell lines. Understanding the molecular mechanisms that fuel 
EMT in response to tipifarnib treatment is important, because EMT has been implicated as a 
common response and mechanism of resistance to other anti-cancer therapeutics. For example, 
induction of EMT promotes resistance to chemo- and radio-therapies in HNSCC cells (de Morais 
et al. 2020), and confers resistance to HER2 inhibition in breast carcinomas (Oliveras-Ferraros et 
al. 2012). For this reason, future studies should also evaluate whether EMT promotes tipifarnib 
resistance.  
Finally, our results show that treatment with the ERK inhibitor SCH772984 induces autophagy in 
HRAS-mutant HNSCC cell lines, but that combined inhibition of ERK and autophagy does not lead 
to an increase in apoptosis. These results suggest that protective autophagy is not a mechanism 
of resistance to ERK inhibition in these cell lines. Induction of protective autophagy is a common 
mechanism of resistance to cancer therapeutics, as it promotes cancer cell survival. For example, 
induction of autophagy has been shown to promote the survival of breast and colorectal cancer 
cells in response to anticancer treatments (Vera-Ramirez et al. 2018) (Zhou et al. 2017). Our 
results in HRAS-mutant HNSCC differ from those seen in KRAS-mutant pancreatic cancer. In KRAS-
mutant PDAC, treatment with SCH772984 increased levels of autophagy, and combined 
inhibition of ERK and autophagy led to increased apoptosis, suggesting protective autophagy as 




the molecular mechanisms through which autophagy is induced in HRAS-mutant HNSCC to help 
explain why autophagy is induced without conferring additional resistance to apoptosis. Because 
SCH772984 does not induce protective autophagy in HRAS-mutant HNSCC as it does in other RAS-
mutant cancers, it would be interesting to consider whether its combination with tipifarnib to 
inhibit MAPK upregulation could be an efficacious treatment strategy. 
These findings are limited to in-vitro experiments performed in three cell lines, so the eventual 
application of our results to HRAS-mutant HNSCC treatment strategies requires more expansive 
work in-vitro and in-vivo. Regardless, these results provide important information regarding the 
ways in which HRAS-mutant HNSCC cell lines may evade targeted therapeutics. 
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